Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 532-540

  Zinonos, Irene ^a   Luo, Ke Wang ^b   Labrinidis, Agatha ^a   Liapis, Vasilios ^a   Hay, Shelley ^a   Panagopoulos, Vasilios ^a   Denichilo, Mark ^a   Ko, Chun Hay ^b   Gar lee Yue, Grace ^b   Bik san Lau, Clara ^b   Ingman, Wendy ^a   Ponomarev, Vladimir ^c   Atkins, Gerald J ^a   Findlay, David M ^a   Zannettino, Andrew C W ^a   Evdokiou, Andreas ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anti resorptive agents; Bisphosphonates; Bone metastasis; Bone resorption; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE REMODELING; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL FUNCTION; CELLULAR DISTRIBUTION; FEMALE; GENE CONSTRUCT; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; LUNG METASTASIS; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN SECRETION; REPORTER GENE; TUMOR GROWTH; ANIMAL; BONE TUMOR; BREAST TUMOR; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ETIOLOGY; GENETIC TRANSFECTION; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NUDE MOUSE; PATHOLOGY; PREVENTION AND CONTROL; SECONDARY; SOFT TISSUE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOLYSIS; OSTEOPROTEGERIN; SOFT TISSUE NEOPLASMS; TRANSFECTION; X-RAY MICROTOMOGRAPHY;

EID: 84902585451     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2468     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Coleman RE, Lipton A, Roodman GD, et al: Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36: 615-620, 2010.
4. Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365: 1396-1405, 2011.
5. Guise TA, Brufsky A and Coleman RE: Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26 (Suppl 3): S3-S20, 2010.
6. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. (Pubitemid 27199902)
7. Tsuda E, Goto M, Mochizuki S, et al: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142, 1997. (Pubitemid 27267548)
8. Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998. (Pubitemid 28213402)
9. Buijs JT and van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer Lett 273: 177-193, 2009.
10. Croucher PI, Shipman CM, Lippitt J, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.
11. Corey E, Brown LG, Kiefer JA, et al: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 1710-1718, 2005. (Pubitemid 40478596)
12. Fisher JL, Thomas-Mudge RJ, Elliott J, et al: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66: 3620-3628, 2006.
13. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH and Corey E: Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977-2983, 2001. (Pubitemid 32963814)
14. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298, 2006. (Pubitemid 44036558)
15. Zinonos I, Labrinidis A, Lee M, et al: Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res 26: 630-643, 2011.
16. Labrinidis A, Diamond P, Martin S, et al: Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15: 1998-2009, 2009.
17. Endo-Munoz L, Cumming A, Rickwood D, et al: Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res 70: 7063-7072, 2010.
18. Luo KW, Ko CH, Yue GG, et al: Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models. Cancer Lett 339: 42-48, 2013.
19. Body JJ, Diel IJ, Bell R, et al: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111: 306-312, 2004. (Pubitemid 39201152)
20. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9: 77-85, 2009.
21. Bundred NJ, Campbell ID, Davidson N, et al: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112: 1001-1010, 2008. (Pubitemid 351304583)
22. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65, 1993. (Pubitemid 23059975)
23. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387, 2001. (Pubitemid 33759002)
24. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21: 3150-3157,